WearLinq, a leading provider of wearable health monitoring and diagnosis solutions, today announced the acquisition of AMI Cardiac Monitoring, LLC, an established independent diagnostic testing facility (IDTF) with more than 33 years of expertise in ambulatory cardiac monitoring. This strategic acquisition will fuel WearLinq’s capacity to offer expansive clinical services across all 50 states and provide more patients access to its eWave 6-lead wearable ECG monitor, which recently received FDA 510(k) clearance. This announcement comes on the heels of a successful close of $6.7 million in early-stage investment from SpringTide, Social Impact Capital, Amino Capital, Berkeley Catalyst Fund, Human Longevity and angels from iRhythm and AliveCor.
“The astute clinical capabilities of AMI combined with the advanced technology of WearLinq will create a tremendously productive partnership,” said Konrad Morzkowski, CEO of WearLinq. “AMI and WearLinq share the same values and visions of providing excellent services for patients and clinical facilities. This synergy enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients and will undoubtedly position us as market leaders very soon.”
One in three people will develop atrial fibrillation (AFib) during their lifetime. AFib increases the risk of stroke fivefold and most commonly leads to heart failure. The current standard of care leaves many patients undiagnosed and untreated, with over 30% receiving false negatives and re-testing within 6 months. In response, WearLinq has built the best diagnostic solution to address these challenges.
The eWave 6-lead ECG device by WearLinq marks a significant technological leap in ambulatory cardiac monitoring, providing cardiologists with a detailed, multidimensional view of the heart, ensuring P-wave visibility and exceptional ECG clarity. It works with the patient’s smartphone, allowing for long-term monitoring with convenient recharging in an AirPods-like case and magnetically attaches to WearLinq's skin-like (patent pending) adhesive patches.
“We are excited to join forces with WearLinq, a company at the forefront of cardiac monitoring innovation. This partnership aligns perfectly with our mission to provide exceptional diagnostic services,” said Dorothy Glodek, Founder of AMI Cardiac Monitoring, LLC. “By integrating WearLinq’s advanced 6-lead ECG technology with our extensive clinical expertise, we can offer unparalleled cardiac care to patients nationwide. Together, we are set to revolutionize the field of ambulatory cardiac monitoring, ensuring more accurate diagnoses and improved patient outcomes.”
Designed with patient comfort and clinical accuracy in mind, the WearLinq ECG device is wearable and minimally intrusive. It allows patients to maintain their lifestyle while continuously monitoring their cardiac health. Integrated with a state-of-the-art cloud platform, the device ensures near real-time data analysis and actionable insights for healthcare providers.
“This is just the beginning; we have an exciting pipeline of AI products to further empower patients and providers, as well as take our reach beyond cardiac monitoring,” adds Morzkowski. “We are dedicated to continuous innovation and expanding our impact across the healthcare spectrum.”
Additionally, industry veteran Joe Knight, joint inventor of iRhythm’s ZioPatch, has joined WearLinq’s Board of Directors.
For more information about WearLinq and its innovative solutions, please visit wearlinq.com.
About WearLinq
WearLinq is a leading provider of health monitoring and diagnosis solutions, dedicated to enhancing patient care and clinical outcomes. With a focus on harnessing cutting-edge technology and providing actionable insights, WearLinq is set to elevate the standard of care.
About AMI Cardiac Monitoring, LLC
AMI Cardiac Monitoring, LLC is a leading provider of ambulatory heart monitoring services and diagnostic technologies across the United States. With over 30 years of experience, AMI Cardiac Monitoring is committed to enhancing patient outcomes by delivering accurate, timely, and actionable cardiac data. Our state-of-the-art diagnostic tools and dedicated support team ensure healthcare providers can offer exceptional care to patients experiencing cardiac issues. AMI Cardiac Monitoring continues to set industry standards in reliability, innovation, and patient care. For more information, please visit www.amicardiac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521325743/en/
Contacts
Josh Heath
josh@springtide.com
